Second, robust detection of targetable fusions (NTRK, RET) could help with targeted therapy in the case of poor outcomes (eg, progression following treatment with radioactive iodine) or in the neoadjuvant setting. Finally, the genomic information in this study could help expand understanding of pediatric thyroid (cancer) biology. The gene discussed is RET; the disease is cancer.